UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Sabra Health Care REIT

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Sabra Health Care REIT

, and slightly raised its price target from $23.00 to $24.00. Jefferies noted, “SBRA continues to successfully reduce exposure to both SUNH and the SNF sector through accretive acquisitions. We still see upside via: 1) multiple expansion through further portfolio diversification, and 2) earnings accretion from acquisitions. Raising PT to $24 and maintaining Buy rating.” Sabra Health Care REIT closed on Tuesday at $21.50.